Company Overview and News

 
MDXHealth SA 2018 Q2 - Results - Earnings Call Slides

2018-08-30 seekingalpha
The following slide deck was published by MDXHealth SA in conjunction with their 2018 Q2 earnings call.
MXDHF MDXH

8
MDXHealth SA (MXDHF) CEO Jan Groen on Q2 2018 Results - Earnings Call Transcript

2018-08-30 seekingalpha
Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to today's MDxHealth Half One 2018 Results Conference Call. [Operator Instructions]
MXDHF EXAS MDXH

8
MDxHealth (R) : MDxHealth communique ses résultats financiers pour le premier semestre 2018

2018-08-30 globenewswire
COMMUNIQUÉ DE PRESSE INFORMATIONS RÉGLEMENTÉES RAPPORT FINANCIER INTERMÉDIAIRE Des progrès d'exploitation satisfaisants et une croissance solide à deux chiffres des volumes de tests cliniques
EXAS MDXH

8
MDxHealth (R): MDxHealth Halfjaarbericht 2018

2018-08-30 globenewswire
Conference call voor analisten en beleggers vandaag om 15:00 CET / 09:00 EST, details aan het eind van dit bericht
EXAS MDXH

8
MDxHealth (R): MDxHealth Reports Half Year 2018 Results

2018-08-30 globenewswire
IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, August 30, 2018 - MDxHealth SA (Euronext: MDXH.BR), today announced financial results for the half year ended June 30, 2018 and provided an update on its strategic outlook.
EXAS MDXH

 
MDxHealth (R): El test SelectMDx coste-efectivo en Cuatro Países Europeos

2018-08-28 globenewswire
Ahorro potencial en los costes de atención médica para los proveedores de atención sanitaria en Francia, Alemania, Italia y España de más de € 300 millones
MDXH

 
MDxHealth (R): SelectMDx-test van MDxHealth kostenefficiënt in vier Europese landen

2018-08-28 globenewswire
Potentiële besparingen op de kosten van gezondheidszorg in Frankrijk, Duitsland, Italië en Spanje van meer dan € 300 miljoen
MDXH

 
MDxHealth (R): SelectMDx Cost-effective in Four European Countries

2018-08-28 globenewswire
IRVINE, CA, and HERSTAL, BELGIUM - 07.00 CEST, 28 August 2018 - MDxHealth SA (Euronext: MDXH.BR) or the "Company" today announces that a study validating the cost-effectiveness of SelectMDx for Prostate Cancer, a non-invasive 'liquid biopsy' to identify patients at increased risk of aggressive prostate cancer, has been published online by the journal Prostate Cancer and Prostatic Diseases.
MDXH

 
MDxHealth (R): SelectMDx Kosteneffektiv in vier europäischen Ländern

2018-08-28 globenewswire
PRESSEMITTEILUNG ANGEPASSTE INFORMATION Mögliche Potenzielle Senkung der Krankheitskosten von mehr als 300 Millionen Euro in Frankreich, Deutschland, Italien und Spanien
MDXH

 
MDxHealth (R): Convenienza economica del SelectMDx in quattro nazioni Europee

2018-08-28 globenewswire
Risparmio potenziale nei costi della Sanità in Francia, Germania, Italia e Spagna per oltre €300 milioni
MDXH

 
MDxHealth (R) : SelectMDx : rapport coût-effectivité positif dans quatre pays européens

2018-08-28 globenewswire
Une économie potentielle de plus de 300 millions d'euros sur les soins de santé en France, en Allemagne, en Italie et en Espagne
MDXH

 
MDxHealth (R): SelectMDx Cost-effective in Four European Countries

2018-08-28 globenewswire
IRVINE, CA, and HERSTAL, BELGIUM - 07.00 CEST, 28 August 2018 - MDxHealth SA (Euronext: MDXH.BR) worldwide leading in molecular diagnostics for urologic cancers, today announces that a study validating the cost-effectiveness of SelectMDx for Prostate Cancer, a non-invasive 'liquid biopsy' test to identify patients at increased risk of aggressive prostate cancer, has been published online by the journal Prostate Cancer and Prostatic Diseases.
MDXH

 
MDxHealth (R) : Avis de publication des résultats semestriels 2018

2018-08-10 globenewswire
Une conférence téléphonique pour les analystes et les investisseurs est prévue le 30 août 2018 à 15:00 CET
MDXH

 
MDxHealth (R) : MDxHealth: Déclaration de Transparence d'un Actionnaire

2018-08-10 globenewswire
IRVINE, CA, et HERSTAL (BELGIQUE) - le 7 août 2018 - MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" ou la "Société"), a annoncé avoir reçu le 3 août 2018 la notification des participations significatives suivante conformément à la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions sont admises à la négociation sur un marché réglementé et portant des dispositions diverses (la «Loi Belge relative à la Transparence»).
MDXH

 
MDxHealth (R): MDxHealth Shareholder Transparency Declaration

2018-08-10 globenewswire
HERSTAL, BELGIUM and IRVINE, CA - August 7, 2018 - MDxHealth SA (Euronext Brussels: MDXH) ("MDxHealth" or the "Company"), announced that it received on August 3, 2018 the following notification of significant shareholdings in accordance with the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the "Belgian Transparency Act").
MDXH

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...